結核病治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、按療法、按給藥途徑、按劑型、按配銷通路、按地區和競爭進行細分，2020 年至 2030 年

2024 年全球結核病治療市場價值為 21.8 億美元，預計到 2030 年將達到 29.4 億美元，複合年成長率為 5.05%。該市場是傳染病治療領域的一個重要領域，受益於持續的全球需求，尤其是抗藥性結核病發病率的上升。儘管結核病治療領域的利潤率一直較低，但它仍具有巨大的公共衛生價值和長期商業潛力。在全球病例數量穩定以及捐助者和公共機構大量資金的支持下，各國政府、衛生機構和製藥公司越來越重視開發創新結核病治療方法。隨著下一代藥物開發（尤其是二線療法）的興起，能夠平衡成本效益、適應監管環境並建立策略合作的公司將能夠確保永續的競爭優勢。

關鍵市場促進因素

全球結核病負擔沉重

主要市場挑戰

藥物研發資金不足且商業激勵有限

主要市場趨勢

轉向更短、更有效的治療方案

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：結核病治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疾病類型（活動性結核病、潛伏性結核病）
  • 按療法（一線療法、二線療法）
  • 依給藥途徑（口服、腸胃外、其他）
  • 按劑型（片劑、膠囊、注射劑、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美結核病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲結核病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太結核病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲結核病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲結核病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球結核病治療市場：SWOT 分析

第 14 章：競爭格局

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

The Global Tuberculosis Therapeutics Market was valued at USD 2.18 billion in 2024 and is projected to reach USD 2.94 billion by 2030, growing at a CAGR of 5.05%. Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development-particularly in second-line therapies-on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.

Key Market Drivers

High Global Burden of Tuberculosis

The global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.

Key Market Challenges

Inadequate Funding and Limited Commercial Incentives for Drug Development

The concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.

Key Market Trends

Shift Toward Shorter, More Effective Treatment Regimens

There is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.

Key Market Players

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

Report Scope:

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

• Active TB
• Latent TB

Tuberculosis Therapeutics Market, By Therapy:

• First-Line Therapy
• Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

• Oral
• Parenteral
• Others

Tuberculosis Therapeutics Market, By Dosage Form:

• Tablets
• Capsules
• Injection
• Others

Tuberculosis Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Tuberculosis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Tuberculosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Active TB, Latent TB)
  • 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy
  • 6.2.3. By Route of Administration
  • 6.2.4. By Dosage Form
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Dosage Form
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Dosage Form
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Dosage Form
      • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy
  • 7.2.3. By Route of Administration
  • 7.2.4. By Dosage Form
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Dosage Form
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Tuberculosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Dosage Form
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Tuberculosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Dosage Form
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Tuberculosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Dosage Form
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Dosage Form
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy
  • 8.2.3. By Route of Administration
  • 8.2.4. By Dosage Form
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Tuberculosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Dosage Form
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Tuberculosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Dosage Form
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Dosage Form
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Dosage Form
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Dosage Form
      • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy
  • 9.2.3. By Route of Administration
  • 9.2.4. By Dosage Form
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Dosage Form
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Dosage Form
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Dosage Form
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy
  • 10.2.3. By Route of Administration
  • 10.2.4. By Dosage Form
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Dosage Form
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Dosage Form
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Dosage Form
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Johnson & Johnson Services, Inc.
• 14.3. Eli Lilly and Company
• 14.4. Mylan Inc.
• 14.5. Teva Pharmaceutical Industries Ltd
• 14.6. Sanofi
• 14.7. Novartis AG
• 14.8. Sun Pharmaceutical Industries Ltd
• 14.9. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer